Company intelligence / Profile preview
Latus Bio
Philadelphia, Pennsylvania, United Stateslatusbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Latus has demonstrated MSH3 knockdown via an artificial miRNA packaged in their novel AAV-DB-3 capsid in a mouse model of HD, resulting in reductions in somatic instability at levels predicted to yield potential clinical benefits[6]. Their proprietary AAV capsids have shown high gene expression in precise CNS locations with cellular specificity and minimal off-tissue activity in non-human primate studies[2][3].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- AAV gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Latus Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Latus Bio.